Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
<p><strong>Background</strong></p> COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply constraints are considering administer...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2021
|
| _version_ | 1797081501345513472 |
|---|---|
| author | Flaxman, A Marchevsky, NG Jenkin, D Aboagye, J Aley, PK Angus, B Belij-Rammerstorfer, S Bibi, S Bittaye, M Cappuccini, F Cicconi, P Clutterbuck, EA Davies, S Dejnirattisai, W Dold, C Ewer, KJ Folegatti, PM Fowler, J Hill, AVS Kerridge, S Minassian, AM Mongkolsapaya, J Mujadidi, YF Plested, E Ramasamy, MN Robinson, H Sanders, H Sheehan, E Smith, H Snape, MD Song, R Woods, D Screaton, G Gilbert, SC Voysey, M Pollard, AJ Lambe, T |
| author2 | Oxford COVID Vaccine Trial group |
| author_facet | Oxford COVID Vaccine Trial group Flaxman, A Marchevsky, NG Jenkin, D Aboagye, J Aley, PK Angus, B Belij-Rammerstorfer, S Bibi, S Bittaye, M Cappuccini, F Cicconi, P Clutterbuck, EA Davies, S Dejnirattisai, W Dold, C Ewer, KJ Folegatti, PM Fowler, J Hill, AVS Kerridge, S Minassian, AM Mongkolsapaya, J Mujadidi, YF Plested, E Ramasamy, MN Robinson, H Sanders, H Sheehan, E Smith, H Snape, MD Song, R Woods, D Screaton, G Gilbert, SC Voysey, M Pollard, AJ Lambe, T |
| author_sort | Flaxman, A |
| collection | OXFORD |
| description | <p><strong>Background</strong></p>
COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply constraints are considering administering a third dose. We assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first and second dose, and response to a third dose as a booster given 28–38 weeks after the second dose.
<p><strong>Methods</strong></p>
In this substudy, volunteers aged 18–55 years who were enrolled in the phase 1/2 (COV001) controlled trial in the UK and had received either a single dose or two doses of 5 × 1010 viral particles were invited back for vaccination. Here we report the reactogenicity and immunogenicity of a delayed second dose (44–45 weeks after first dose) or a third dose of the vaccine (28–38 weeks after second dose). Data from volunteers aged 18–55 years who were enrolled in either the phase 1/2 (COV001) or phase 2/3 (COV002), single-blinded, randomised controlled trials of ChAdOx1 nCoV-19 and who had previously received a single dose or two doses of 5 × 1010 viral particles are used for comparison purposes. COV001 is registered with ClinicalTrials.gov, NCT04324606, and ISRCTN, 15281137, and COV002 is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137, and both are continuing but not recruiting.
<p><strong>Findings</strong></p>
Between March 11 and 21, 2021, 90 participants were enrolled in the third-dose boost substudy, of whom 80 (89%) were assessable for reactogenicity, 75 (83%) were assessable for evaluation of antibodies, and 15 (17%) were assessable for T-cells responses. The two-dose cohort comprised 321 participants who had reactogenicity data (with prime-boost interval of 8–12 weeks: 267 [83%] of 321; 15–25 weeks: 24 [7%]; or 44–45 weeks: 30 [9%]) and 261 who had immunogenicity data (interval of 8–12 weeks: 115 [44%] of 261; 15–25 weeks: 116 [44%]; and 44–45 weeks: 30 [11%]). 480 participants from the single-dose cohort were assessable for immunogenicity up to 44–45 weeks after vaccination. Antibody titres after a single dose measured approximately 320 days after vaccination remained higher than the titres measured at baseline (geometric mean titre of 66·00 ELISA units [EUs; 95% CI 47·83–91·08] vs 1·75 EUs [1·60–1·93]). 32 participants received a late second dose of vaccine 44–45 weeks after the first dose, of whom 30 were included in immunogenicity and reactogenicity analyses. Antibody titres were higher 28 days after vaccination in those with a longer interval between first and second dose than for those with a short interval (median total IgG titre: 923 EUs [IQR 525–1764] with an 8–12 week interval; 1860 EUs [917–4934] with a 15–25 week interval; and 3738 EUs [1824–6625] with a 44–45 week interval). Among participants who received a third dose of vaccine, antibody titres (measured in 73 [81%] participants for whom samples were available) were significantly higher 28 days after a third dose (median total IgG titre: 3746 EUs [IQR 2047–6420]) than 28 days after a second dose (median 1792 EUs [IQR 899–4634]; Wilcoxon signed rank test p=0·0043). T-cell responses were also boosted after a third dose (median response increased from 200 spot forming units [SFUs] per million peripheral blood mononuclear cells [PBMCs; IQR 127–389] immediately before the third dose to 399 SFUs per milion PBMCs [314–662] by day 28 after the third dose; Wilcoxon signed rank test p=0·012). Reactogenicity after a late second dose or a third dose was lower than reactogenicity after a first dose.
<p><strong>Interpretation</strong></p>
An extended interval before the second dose of ChAdOx1 nCoV-19 leads to increased antibody titres. A third dose of ChAdOx1 nCoV-19 induces antibodies to a level that correlates with high efficacy after second dose and boosts T-cell responses.
<p><strong>Funding</strong></p>
UK Research and Innovation, Engineering and Physical Sciences Research Council, National Institute for Health Research, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research Oxford Biomedical Research Centre, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Thames Valley and South Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome. |
| first_indexed | 2024-03-07T01:15:12Z |
| format | Journal article |
| id | oxford-uuid:8e6aa1ae-0337-4550-afe7-3fe8f95bfef1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:15:12Z |
| publishDate | 2021 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:8e6aa1ae-0337-4550-afe7-3fe8f95bfef12022-03-26T22:57:54ZReactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8e6aa1ae-0337-4550-afe7-3fe8f95bfef1EnglishSymplectic ElementsElsevier2021Flaxman, AMarchevsky, NGJenkin, DAboagye, JAley, PKAngus, BBelij-Rammerstorfer, SBibi, SBittaye, MCappuccini, FCicconi, PClutterbuck, EADavies, SDejnirattisai, WDold, CEwer, KJFolegatti, PMFowler, JHill, AVSKerridge, SMinassian, AMMongkolsapaya, JMujadidi, YFPlested, ERamasamy, MNRobinson, HSanders, HSheehan, ESmith, HSnape, MDSong, RWoods, DScreaton, GGilbert, SCVoysey, MPollard, AJLambe, TOxford COVID Vaccine Trial group<p><strong>Background</strong></p> COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between the first and second dose becomes longer. Conversely, countries with no supply constraints are considering administering a third dose. We assessed the persistence of immunogenicity after a single dose of ChAdOx1 nCoV-19 (AZD1222), immunity after an extended interval (44–45 weeks) between the first and second dose, and response to a third dose as a booster given 28–38 weeks after the second dose. <p><strong>Methods</strong></p> In this substudy, volunteers aged 18–55 years who were enrolled in the phase 1/2 (COV001) controlled trial in the UK and had received either a single dose or two doses of 5 × 1010 viral particles were invited back for vaccination. Here we report the reactogenicity and immunogenicity of a delayed second dose (44–45 weeks after first dose) or a third dose of the vaccine (28–38 weeks after second dose). Data from volunteers aged 18–55 years who were enrolled in either the phase 1/2 (COV001) or phase 2/3 (COV002), single-blinded, randomised controlled trials of ChAdOx1 nCoV-19 and who had previously received a single dose or two doses of 5 × 1010 viral particles are used for comparison purposes. COV001 is registered with ClinicalTrials.gov, NCT04324606, and ISRCTN, 15281137, and COV002 is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137, and both are continuing but not recruiting. <p><strong>Findings</strong></p> Between March 11 and 21, 2021, 90 participants were enrolled in the third-dose boost substudy, of whom 80 (89%) were assessable for reactogenicity, 75 (83%) were assessable for evaluation of antibodies, and 15 (17%) were assessable for T-cells responses. The two-dose cohort comprised 321 participants who had reactogenicity data (with prime-boost interval of 8–12 weeks: 267 [83%] of 321; 15–25 weeks: 24 [7%]; or 44–45 weeks: 30 [9%]) and 261 who had immunogenicity data (interval of 8–12 weeks: 115 [44%] of 261; 15–25 weeks: 116 [44%]; and 44–45 weeks: 30 [11%]). 480 participants from the single-dose cohort were assessable for immunogenicity up to 44–45 weeks after vaccination. Antibody titres after a single dose measured approximately 320 days after vaccination remained higher than the titres measured at baseline (geometric mean titre of 66·00 ELISA units [EUs; 95% CI 47·83–91·08] vs 1·75 EUs [1·60–1·93]). 32 participants received a late second dose of vaccine 44–45 weeks after the first dose, of whom 30 were included in immunogenicity and reactogenicity analyses. Antibody titres were higher 28 days after vaccination in those with a longer interval between first and second dose than for those with a short interval (median total IgG titre: 923 EUs [IQR 525–1764] with an 8–12 week interval; 1860 EUs [917–4934] with a 15–25 week interval; and 3738 EUs [1824–6625] with a 44–45 week interval). Among participants who received a third dose of vaccine, antibody titres (measured in 73 [81%] participants for whom samples were available) were significantly higher 28 days after a third dose (median total IgG titre: 3746 EUs [IQR 2047–6420]) than 28 days after a second dose (median 1792 EUs [IQR 899–4634]; Wilcoxon signed rank test p=0·0043). T-cell responses were also boosted after a third dose (median response increased from 200 spot forming units [SFUs] per million peripheral blood mononuclear cells [PBMCs; IQR 127–389] immediately before the third dose to 399 SFUs per milion PBMCs [314–662] by day 28 after the third dose; Wilcoxon signed rank test p=0·012). Reactogenicity after a late second dose or a third dose was lower than reactogenicity after a first dose. <p><strong>Interpretation</strong></p> An extended interval before the second dose of ChAdOx1 nCoV-19 leads to increased antibody titres. A third dose of ChAdOx1 nCoV-19 induces antibodies to a level that correlates with high efficacy after second dose and boosts T-cell responses. <p><strong>Funding</strong></p> UK Research and Innovation, Engineering and Physical Sciences Research Council, National Institute for Health Research, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research Oxford Biomedical Research Centre, Chinese Academy of Medical Sciences Innovation Fund for Medical Science, Thames Valley and South Midlands NIHR Clinical Research Network, AstraZeneca, and Wellcome. |
| spellingShingle | Flaxman, A Marchevsky, NG Jenkin, D Aboagye, J Aley, PK Angus, B Belij-Rammerstorfer, S Bibi, S Bittaye, M Cappuccini, F Cicconi, P Clutterbuck, EA Davies, S Dejnirattisai, W Dold, C Ewer, KJ Folegatti, PM Fowler, J Hill, AVS Kerridge, S Minassian, AM Mongkolsapaya, J Mujadidi, YF Plested, E Ramasamy, MN Robinson, H Sanders, H Sheehan, E Smith, H Snape, MD Song, R Woods, D Screaton, G Gilbert, SC Voysey, M Pollard, AJ Lambe, T Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) |
| title | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) |
| title_full | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) |
| title_fullStr | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) |
| title_full_unstemmed | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) |
| title_short | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) |
| title_sort | reactogenicity and immunogenicity after a late second dose or a third dose of chadox1 ncov 19 in the uk a substudy of two randomised controlled trials cov001 and cov002 |
| work_keys_str_mv | AT flaxmana reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT marchevskyng reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT jenkind reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT aboagyej reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT aleypk reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT angusb reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT belijrammerstorfers reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT bibis reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT bittayem reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT cappuccinif reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT cicconip reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT clutterbuckea reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT daviess reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT dejnirattisaiw reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT doldc reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT ewerkj reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT folegattipm reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT fowlerj reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT hillavs reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT kerridges reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT minassianam reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT mongkolsapayaj reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT mujadidiyf reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT plestede reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT ramasamymn reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT robinsonh reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT sandersh reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT sheehane reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT smithh reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT snapemd reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT songr reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT woodsd reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT screatong reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT gilbertsc reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT voyseym reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT pollardaj reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 AT lambet reactogenicityandimmunogenicityafteralateseconddoseorathirddoseofchadox1ncov19intheukasubstudyoftworandomisedcontrolledtrialscov001andcov002 |